Sativa Group PLC Joins the ACI Toxicology Study to Further its Commitment to Novel Food Compliance

Rhea-AI Summary

Stillcanna Inc. announced that its partner, Sativa Group PLC, has joined the Association for the Cannabinoid Industry (ACI) to participate in a toxicology study aimed at compliance with Novel Food regulations. This initiative is crucial for ensuring the safety of CBD products post-March 31, 2021. Sativa's team is working closely with ACI to meet rigorous quality standards, with raw materials and final products undergoing third-party testing. The company intends to submit its Novel Food application, further enhancing its commitment to high-quality, compliant products.

Positive

• Sativa Group's membership in ACI's toxicology study supports compliance with Novel Food regulations.
• Submission of Novel Food application may enhance market access for CBD products.
• Third-party testing ensures high safety and quality standards for products.

Negative

• Products must comply with strict regulations by March 31, 2021, or risk market removal.

VANCOUVER, BC / ACCESSWIRE / September 25, 2020 / Stillcanna Inc. (CSE:STIL) (the "Company") is pleased to announce that as part of the Sativa Group PLC's ("Sativa") ongoing commitment to continually deliver the highest level of regulatory compliance and substantiate ‘CBD you can trust', Sativa has become a member of the Association for the Cannabinoid Industry (the "ACI") Novel Food consortium and it's landmark toxicology study, which will augment the submission of its own Novel Food application dossier.

The toxicology study will provide safety data that is required for Novel Food dossiers validated by the FSA, and for products to remain available on the market after March 31, 2021.

Sativa and the Company's team of scientists and quality/compliance professionals in the United Kingdom and Poland have worked with the ACI to ensure its CBD products meet their rigorous quality management criteria.

As part of this regulatory process, the raw CBD ingredients and final products are tested by a leading third-party laboratory, and cultivation, extraction and manufacturing processes and standards are scrutinised, to ensure that Sativa is meeting safety and regulatory standards from seed through to shelf.

The Company is submitting its own novel food application for its portfolio of products and brands, and on behalf of White Label customers.

Henry Lees-Buckley, Chief Executive Office of Sativa, said: "At Sativa, producing the highest quality and compliant products is our number one objective! We welcome the FSA Novel Foods accreditation process and are very pleased to be associated with the ACI in our compliance efforts".

On Behalf of the Board of Directors,

Jason Dussault, Director
For further information, please contact:

Jason Dussault
info@stillcanna.com

Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release.

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Stillcanna's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "will", "expects", "continues to", "plans", "expects", "expects to", or "does not expect", "is expected", "expects", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved".

The forward-looking information and forward-looking statements contained herein include, but are not limited to, the submission of the Novel Foods Application, the membership in the ACI toxicology study, the availability of products beyond March 2021 and the timing of such products, the testing of certain products, the relationships with third parties, the creation of a fully integrated European seed to consumer offering, our supply chain, compliance with European industry regulation, the Novel Foods Accreditation, various unforeseen events could make this statement no longer valid. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements.

In particular, there is no guarantee that that the merger solidifies both companies position as a leader across the entire supply chain, and that they are in a unique position to produce and supply the highest quality products with the lowest possible costs. The forward-looking information and forward-looking statements contained in this news release are made as of the date of this press release, and Stillcanna does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities.

SOURCE: Stillcanna Inc.

View source version on accesswire.com:
https://www.accesswire.com/607781/Sativa-Group-PLC-Joins-the-ACI-Toxicology-Study-to-Further-its-Commitment-to-Novel-Food-Compliance

FAQ

What is the significance of Sativa Group joining the ACI toxicology study related to SCNNF?

Joining the ACI toxicology study is crucial for Sativa Group as it aims to ensure compliance with Novel Food regulations, which is vital for the continued sale of its CBD products.

How does the toxicology study impact Stillcanna's product portfolio SCNNF?

The toxicology study will provide necessary safety data that supports the submission of Stillcanna's Novel Food application, impacting the regulatory status of its product portfolio.

What deadline does Stillcanna face for Novel Food compliance for SCNNF?

Stillcanna must ensure its products are compliant with Novel Food regulations by March 31, 2021, to avoid being removed from the market.